- Home
- DNTH vs FLGT Comparison
DNTH vs FLGT Comparison
Compare DNTH & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- FLGT
- Stock Information
- Founded
- DNTH 2015
- FLGT 2011
- Country
- DNTH United States
- FLGT United States
- Employees
- DNTH N/A
- FLGT N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- FLGT Medical Specialities
- Sector
- DNTH Health Care
- FLGT Health Care
- Exchange
- DNTH Nasdaq
- FLGT Nasdaq
- Market Cap
- DNTH 823.1M
- FLGT 683.5M
- IPO Year
- DNTH N/A
- FLGT 2016
- Fundamental
- Price
- DNTH $20.27
- FLGT $17.11
- Analyst Decision
- DNTH Strong Buy
- FLGT Hold
- Analyst Count
- DNTH 8
- FLGT 2
- Target Price
- DNTH $46.43
- FLGT $28.50
- AVG Volume (30 Days)
- DNTH 291.2K
- FLGT 253.6K
- Earning Date
- DNTH 11-07-2024
- FLGT 11-08-2024
- Dividend Yield
- DNTH N/A
- FLGT N/A
- EPS Growth
- DNTH N/A
- FLGT N/A
- EPS
- DNTH N/A
- FLGT N/A
- Revenue
- DNTH $5,366,000.00
- FLGT $277,761,000.00
- Revenue This Year
- DNTH $44.94
- FLGT N/A
- Revenue Next Year
- DNTH N/A
- FLGT $14.04
- P/E Ratio
- DNTH N/A
- FLGT N/A
- Revenue Growth
- DNTH 51.41
- FLGT N/A
- 52 Week Low
- DNTH $6.58
- FLGT $16.56
- 52 Week High
- DNTH $33.77
- FLGT $30.68
- Technical
- Relative Strength Index (RSI)
- DNTH 22.81
- FLGT 35.11
- Support Level
- DNTH $22.19
- FLGT $16.56
- Resistance Level
- DNTH $28.56
- FLGT $18.61
- Average True Range (ATR)
- DNTH 2.02
- FLGT 1.08
- MACD
- DNTH -0.88
- FLGT -0.33
- Stochastic Oscillator
- DNTH 3.38
- FLGT 12.60
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.